SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 10,000 Shares of Stock

Posted by Mitch Edgeman on Aug 31st, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $8.91, for a total transaction of $89,100.00. Following the sale, the insider directly owned 556,887 shares of the company’s stock, valued at $4,961,863.17. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.
On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH traded up $0.26 during mid-day trading on Monday, reaching $8.40. The stock had a trading volume of 748,702 shares, compared to its average volume of 248,108. The stock has a market capitalization of $704.72 million, a P/E ratio of -7.30 and a beta of 0.96. The firm has a 50 day moving average price of $6.52 and a two-hundred day moving average price of $5.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Read Our Latest Stock Report on SOPH

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS during the 2nd quarter valued at $9,809,000. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the first quarter valued at about $1,772,000. 1492 Capital Management LLC purchased a new position in shares of SOPHiA GENETICS in the fourth quarter valued at about $973,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Finally, Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at about $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.